Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Inclusion Criteria: * Histological confirmed Stage III or IV malignant melanoma * HLA-A\*0201 haplotype * Expected survival of at least 9 months * Willing and able to comply with all trial requirements (e.g. diaries, CTs) * Given written informed consent * Females only if non-reproductive or if they agree to consistently practice an effective and accepted method of contraception Exclusion Criteria: * Any contraindication to any study related test or assessment * Current or planned use of contraindicated concomitant medication * Presence or history of relevant cardiovascular, renal, pulmonary, endocrine, autoimmune, neurological and psychiatric disease * Infection with HIV, HBV or HCV * Pregnancy or lactation or females planning to become pregnant during the study * Abuse of alcohol or other drugs * Use of investigational drug within 30 days before enrolment * Previous participation in a clinical trial with a Qb-based Cytos vaccine.